Provided by Tiger Trade Technology Pte. Ltd.

Beam Therapeutics, Inc.

24.45
-0.6800-2.71%
Volume:593.43K
Turnover:14.55M
Market Cap:2.53B
PE:-29.19
High:24.93
Open:24.84
Low:24.28
Close:25.13
52wk High:38.26
52wk Low:20.23
Shares:103.29M
Float Shares:91.60M
Volume Ratio:0.58
T/O Rate:0.65%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.8376
EPS(LYR):-0.8100
ROE:-8.18%
ROA:-17.01%
PB:2.37
PE(LYR):-30.19

Loading ...

Beam Therapeutics Reports Initial Phase 1/2 Data for BEAM-301 in Glycogen Storage Disease Type Ia Trial

Reuters
·
Yesterday

Wells Fargo Sticks to Its Buy Rating for Beam Therapeutics (BEAM)

TIPRANKS
·
Oct 05

Beam Therapeutics (BEAM) Could Be 52% Undervalued Following Its Lawsuit Over Research Misuse

Simply Wall St.
·
Oct 03

Novartis Bets $7.8 Billion On MRNA Beyond Vaccines

Options & Short Sell
·
Oct 02

From Exoskeletons to AI: ChronoScale's Billion-Dollar Pivot

Tech News Roundup
·
Oct 02

Cathie Wood’s ARK Investment buys 103K shares of Beam Therapeutics today

TIPRANKS
·
Sep 22

Cathie Wood’s ARK Investment buys 271K shares of Beam Therapeutics today

TIPRANKS
·
Sep 10

Wedbush Reaffirms Their Buy Rating on Beam Therapeutics (BEAM)

TIPRANKS
·
Sep 09

JonesTrading Remains a Buy on Beam Therapeutics (BEAM)

TIPRANKS
·
Sep 09

Analysts Conflicted on These Healthcare Names: Amgen (AMGN), Beam Therapeutics (BEAM) and Royalty Pharma (RPRX)

TIPRANKS
·
Sep 09

Shares of Beam Therapeutics Retreat After Updated Trial Data Disappoints

Dow Jones
·
Sep 09

Beam Therapeutics falls -12.7%

TIPRANKS
·
Sep 08

Beam Therapeutics’ BEAM-302 shows efficacy in Phase 1/2 AATD trial

TIPRANKS
·
Sep 08

Beam Therapeutics Presents Updated Clinical Data from the Phase 1/2 Trial of Beam-302 in Alpha-1 Antitrypsin Deficiency (Aatd) at the European Respiratory Society (Ers) Congress 2026

THOMSON REUTERS
·
Sep 08

Beam Therapeutics Presents Updated Clinical Data from the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the European Respiratory Society (ERS) Congress 2026

GlobeNewswire
·
Sep 08

Arm's Haas: AI Could Cure Cancer In Our Lifetime — If The Industry Can Build Enough Chips

AI Industry Frontlines
·
Sep 08

Press Release: Beam Therapeutics Appoints Eric Foster as Chief Commercial Officer

Dow Jones
·
Sep 01

Analysts Offer Insights on Healthcare Companies: Beam Therapeutics (BEAM), OmniAb (OABI) and Astrana Health (ASTH)

TIPRANKS
·
Aug 07

Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Ultragenyx Pharmaceutical (RARE) and Beam Therapeutics (BEAM)

TIPRANKS
·
Aug 05

Evercore ISI Reaffirms Their Buy Rating on Beam Therapeutics (BEAM)

TIPRANKS
·
Aug 05